HK1251551A1 - 氮雜環丁烷衍生物、其製備方法及用途 - Google Patents
氮雜環丁烷衍生物、其製備方法及用途Info
- Publication number
- HK1251551A1 HK1251551A1 HK18110823.2A HK18110823A HK1251551A1 HK 1251551 A1 HK1251551 A1 HK 1251551A1 HK 18110823 A HK18110823 A HK 18110823A HK 1251551 A1 HK1251551 A1 HK 1251551A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- preparation
- method therefor
- azetidine derivative
- azetidine
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510924946 | 2015-12-11 | ||
PCT/CN2016/109036 WO2017097224A1 (zh) | 2015-12-11 | 2016-12-08 | 氮杂环丁烷衍生物、其制备方法及用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1251551A1 true HK1251551A1 (zh) | 2019-02-01 |
Family
ID=59012693
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18109969.8A HK1250707B (zh) | 2015-12-11 | 2018-08-02 | 氮雜環丁烷衍生物、其製備方法及用途 |
HK18110823.2A HK1251551A1 (zh) | 2015-12-11 | 2018-08-22 | 氮雜環丁烷衍生物、其製備方法及用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18109969.8A HK1250707B (zh) | 2015-12-11 | 2018-08-02 | 氮雜環丁烷衍生物、其製備方法及用途 |
Country Status (8)
Country | Link |
---|---|
US (3) | US10159662B2 (zh) |
EP (1) | EP3360878B9 (zh) |
JP (1) | JP6860267B2 (zh) |
CN (1) | CN108137603B (zh) |
DK (1) | DK3360878T3 (zh) |
ES (1) | ES2830446T3 (zh) |
HK (2) | HK1250707B (zh) |
WO (1) | WO2017097224A1 (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3360878B9 (en) * | 2015-12-11 | 2021-05-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Azetidine derivative, preparation method therefor, and use thereof |
US11524961B2 (en) | 2017-01-23 | 2022-12-13 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | JAK kinase inhibitor and preparation method and use thereof |
WO2018223859A1 (zh) * | 2017-06-07 | 2018-12-13 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物的固体形式及其制备方法和用途 |
CN111566095B (zh) | 2017-11-03 | 2024-09-27 | 阿克拉瑞斯治疗股份有限公司 | 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法 |
US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
CN113149993A (zh) * | 2017-12-01 | 2021-07-23 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
US10508113B2 (en) * | 2018-03-12 | 2019-12-17 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
AU2019317625A1 (en) | 2018-08-10 | 2021-02-18 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine ITK inhibitors |
CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
CN111518096B (zh) * | 2019-02-02 | 2022-02-11 | 江苏威凯尔医药科技有限公司 | 两面神激酶jak家族抑制剂及其制备和应用 |
CN113508114B (zh) * | 2019-02-27 | 2024-03-26 | 四川科伦博泰生物医药股份有限公司 | 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途 |
CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
EP3962897A4 (en) | 2019-05-02 | 2022-12-14 | Aclaris Therapeutics, Inc. | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS |
CN110028432A (zh) * | 2019-05-22 | 2019-07-19 | 南京合巨药业有限公司 | 一种(3-氨基-氮杂环丁烷-1-基)-环丙基-甲酮的制备方法 |
BR112021023635A2 (pt) * | 2019-05-28 | 2022-02-01 | Mankind Pharma Ltd | Novos compostos para inibição de janus quinase 1 |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2023174314A1 (zh) | 2022-03-18 | 2023-09-21 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物的用途及治疗方法 |
WO2023226822A1 (zh) * | 2022-05-26 | 2023-11-30 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物治疗病毒感染的方法及用途 |
WO2024148184A1 (en) * | 2023-01-04 | 2024-07-11 | Aerie Pharmaceuticals, Inc. | Compounds and processes for the preparation of jak inhibitors |
WO2024153147A1 (zh) * | 2023-01-18 | 2024-07-25 | 北京普祺医药科技股份有限公司 | 一种氮杂环烷烃化合物、药物组合物及其用途 |
CN116444529B (zh) * | 2023-06-16 | 2023-12-05 | 药康众拓(江苏)医药科技有限公司 | 一种氘代氮杂环丁烷类jak抑制剂及其用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2354140A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
JP5275371B2 (ja) * | 2008-03-11 | 2013-08-28 | インサイト・コーポレイション | Jak阻害剤としてのアゼチジン誘導体およびシクロブタン誘導体 |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
AU2011224484A1 (en) | 2010-03-10 | 2012-09-27 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
AR086983A1 (es) | 2011-06-20 | 2014-02-05 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
US20130310340A1 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
PL3129021T3 (pl) | 2014-04-08 | 2021-05-31 | Incyte Corporation | Leczenie nowotworów złośliwych z komórek b za pomocą skojarzenia inhibitora jak i pi3k |
TWI748941B (zh) | 2015-02-27 | 2021-12-11 | 美商英塞特公司 | Pi3k抑制劑之鹽及製備方法 |
RU2601410C1 (ru) * | 2015-11-13 | 2016-11-10 | ЗАО "Р-Фарм" | {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ |
EP3360878B9 (en) * | 2015-12-11 | 2021-05-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Azetidine derivative, preparation method therefor, and use thereof |
-
2016
- 2016-12-08 EP EP16872413.6A patent/EP3360878B9/en active Active
- 2016-12-08 JP JP2018518690A patent/JP6860267B2/ja active Active
- 2016-12-08 CN CN201680059396.4A patent/CN108137603B/zh active Active
- 2016-12-08 DK DK16872413.6T patent/DK3360878T3/da active
- 2016-12-08 US US15/767,508 patent/US10159662B2/en active Active
- 2016-12-08 ES ES16872413T patent/ES2830446T3/es active Active
- 2016-12-08 WO PCT/CN2016/109036 patent/WO2017097224A1/zh active Application Filing
-
2018
- 2018-08-02 HK HK18109969.8A patent/HK1250707B/zh unknown
- 2018-08-22 HK HK18110823.2A patent/HK1251551A1/zh unknown
- 2018-10-24 US US16/169,780 patent/US20190060291A1/en not_active Abandoned
-
2020
- 2020-01-16 US US16/745,206 patent/US11045455B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3360878A4 (en) | 2019-03-06 |
ES2830446T3 (es) | 2021-06-03 |
CN108137603B (zh) | 2019-10-18 |
CN108137603A (zh) | 2018-06-08 |
WO2017097224A1 (zh) | 2017-06-15 |
HK1250707B (zh) | 2020-07-03 |
EP3360878A1 (en) | 2018-08-15 |
US20190060291A1 (en) | 2019-02-28 |
EP3360878B1 (en) | 2020-09-16 |
US20200147062A1 (en) | 2020-05-14 |
DK3360878T3 (da) | 2020-11-09 |
US11045455B2 (en) | 2021-06-29 |
JP6860267B2 (ja) | 2021-04-14 |
JP2018536634A (ja) | 2018-12-13 |
EP3360878B9 (en) | 2021-05-05 |
US20180289680A1 (en) | 2018-10-11 |
US10159662B2 (en) | 2018-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251551A1 (zh) | 氮雜環丁烷衍生物、其製備方法及用途 | |
HK1255566A1 (zh) | 氧代吡啶酰胺類衍生物、其製備方法及其在醫藥上的應用 | |
PL3181560T3 (pl) | Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie | |
PL3139979T3 (pl) | Jednostka, nebulizator i sposób | |
GB2527607B (en) | Encoder, decoder and method | |
GB2523348B (en) | Encoder, decoder and method | |
EP3246327A4 (en) | 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof | |
GB2528959C (en) | Encoder, decoder and methods | |
GB2523347B (en) | Encoder, decoder and method | |
EP3372596A4 (en) | METHOD FOR THE PRODUCTION OF TEDIZOLIDE, TEDIZOLIDE INTERMEDIATE PRODUCTION AND METHOD OF MANUFACTURING THEREOF | |
EP3395366C0 (en) | METHOD FOR DESIGNING A DRUG, DRUG OBTAINED AND ASSOCIATED APPLICATION | |
EP3112351A4 (en) | Naphthylamide compound, preparation method and use thereof | |
GB2528460B (en) | Encoder, decoder and method | |
EP3157016A4 (en) | Scintillator, preparing method thereof, and application thereof | |
HK1243437A1 (zh) | 一類三肽化合物及其製備方法與應用 | |
HK1243995A1 (zh) | α-細辛醇酯及其製備方法與應用 | |
EP3107320A4 (en) | Apparatus, program, and method | |
PL3360863T3 (pl) | Pochodna i związek pośredni etomidatu, sposób przygotowania i zastosowanie | |
HUE053535T2 (hu) | Eljárás kollagénhozam növelésére, és az annak alkalmazásával elõállított kollagén | |
IL250223B (en) | A method for the preparation of the pyrimidine-1-ol compound, and its intermediates | |
EP3239168A4 (en) | Conotoxin peptide -cptx-btl02, preparation method therefor, and uses thereof | |
PT3159314T (pt) | Unidade de clarificação, método e utilização | |
EP3239169A4 (en) | Conotoxin peptide -cptx-btl05, preparation method therefor, and uses thereof | |
PT3236877T (pt) | Disposição que compreende um implante e um processo |